MMRGlobal Awarded Another International Patent to Fight Cancer, Company Benefits From Worldwide HIT & Biotech Patents

MMRGlobal Awarded Another International Patent to Fight Cancer, Company 
Benefits From Worldwide HIT & Biotech Patents 
LOS ANGELES, CA -- (Marketwired) -- 04/22/13 --  MMRGlobal, Inc.
(OTCQB: MMRF) ("MMR") today announced that the Australian Patent
Office has issued a Notice of Allowance (NOA) for the Company's
anti-CD20 monoclonal antibody assets, #2007338607, under the title,
"Antibodies and Methods for Making and Using Them." The patent
application was originally filed on September 14, 2007. The
Australian NOA is significant to the Company in that it reinforces
the value of the U.S. antibody patent that was announced by the
Company on April 15th, 2013 and the similar antibody patent issued in
Mexico in August 2012. These patents for the Company's anti-CD20
monoclonal antibodies have particular utility in fighting cancers and
are considered important assets of the Company based on benefits and
commercial value demonstrated by Rituxan(R), an anti-CD20 monoclonal
antibody with reported sales of USD $7.285 billion in 2012, which is
due to go off patent in 2015. Additional patent applications for the
Company's antibodies are pending in a number of other countries
including Brazil, Canada, China, Hong Kong, India, Europe, Japan and
Korea. In addition to its biotech patents, MMR currently has seven
U.S. Health Information Technology (HIT) patents covering inventions
pertaining to Personal Health Records (PHRs), Patient Portals and
other Electronic Health Record systems which were the subject of a
recent report on Personal Health Records and in particular the value
of the Company's U.S. HIT patent portfolio (available at
http://michaelbass.com/PDF/Patent_Valuation.pdf). 
According to Robert H. Lorsch, MMRGlobal CEO, "Since the inception of
MMR in 2005, the Company has incurred more than 40 million dollars in
expenses to get our HIT products and services and related IP to where
it is today. I am optimistic as I watch consumers and employers
finally understand and embrace the importance of having a Personal
Health Record. This is evidenced by activity everywhere, including
the current Public Voting Campaign in New York at
http://patientportalfornewyorkers.org and similar programs which we
believe also may infringe on the Company's intellectual 
property.
We're finally seeing the acceptance of health IT products and
services such as Personal Health Records and patient portals in a
market being driven globally by government regulations and usage
mandates such as Meaningful Use Stage 2 in the United States. Our
domestic Health Information Technology patent portfolio has been
valued at as much as 1.1 billion dollars only months ago. If you
discount that number by 80% it is still nearly 10 times the market
cap of the Company. Also, the valuation does not include any value of
the Company's international HIT IP or any value of the biotech assets
already the subject of an eight figure license agreement. Bottom line
is there appears to be tremendous upside in our Company." 
The Company has demonstrated its ability to license its biotech and
health information technology patents and other IP. The Company has
also filed claims for patent infringement against Walgreen Co. and
Quest Diagnostics, Inc. Both were filed in the United States District
Court for the Central District of California, case numbers CV
13-00631 and CV 13-00631, respectively. The claims are available on
the court's website http://www.pacer.gov/, along with at least one
additional infringement complaint. The Company is planning on
bringing additional actions and is using the law firm of Liner Grode
Stein Yankelevitz Sunshine Regenstreif & Taylor LLP to pursue
licensing and infringement matters for both the Company's health IT
patents and its biotech IP. 
MMR's HIT patent portfolio includes seven U.S. patents along with
additional applications and continuation applications with nearly 400
claims. The Company also has health IT patents and patent
applications in other countries of commercial interest including
Australia, Singapore, New Zealand, Mexico, Japan, Canada, Hong Kong,
South Korea, Israel, and European nations. The Company acquired its
biotechnology portfolio as a result of a reverse merger with
Favrille, Inc., a biopharmaceutical company, in January 2009.
Favrille invested more than $100 million in research and development
on its FavId(TM)/Specifid(TM) vaccine trials and use of customized
tumor cells to treat lymphoma patients and other technologies. MMR's
biotech assets include an extensive portfolio including its anti-CD20
monoclonal antibodies, data from vaccine trials, thousands of patient
tumor samples and other intellectual property of which the Company
has been advised by experts may have inestimable value.  
About MMRGlobal
 MMRGlobal, Inc., through its wholly-owned operating
subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use
online Personal Health Records ("PHRs") and electronic safe deposit
box storage solutions, serving consumers, healthcare professionals,
employers, insurance companies, financial institutions, retail
pharmacies, and professional organizations and affinity groups. The
MyMedicalRecords PHR enables individuals and families to access their
medical records and other important documents, such as birth
certificates, passports, insurance policies and wills, anytime from
anywhere using the Internet. MyMedicalRecords is built on
proprietary, patented technologies to allow documents, images and
voicemail messages to be transmitted and stored in the system using a
variety of methods, including fax, phone, or file upload without
relying on any specific electronic medical record platform to
populate a user's account. The Company's professional offering,
MMRPro, is designed to give physicians' offices an easy and
cost-effective solution to digitizing paper-based medical records and
sharing them with patients through an integrated patient portal.
Through its merger with Favrille, Inc. in January 2009, the Company
acquired intellectual property biotech assets that include anti-CD20
antibodies and data and samples from its FavId(TM)/Specifid(TM)
vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's
lymphoma. To learn more about MMRGlobal, Inc. visit
www.mmrglobal.com. View demos and video tutorials of the Company's
products and services at www.mmrtheater.com. 
Forward-Looking Statements 
 All statements in this press release
that are not strictly historical in nature, including, without
limitation, intellectual property enforcement actions, infringement
claims or litigation, intellectual property licenses, and future
performance, management's expectations, beliefs, intentions,
estimates or projections, constitute "forward-looking statements."
Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the Company's actual
results to be materially different from historical results or from
any results expressed or implied by such forward-looking statements.
Some can be identified by the use of words (and their derivations)
such as "need," "possibility," "potential," "intend," "offer,"
"development," "if," "negotiate," "when," "begun," "believe,"
"achieve," "will," "estimate," "expect," "maintain," "plan," and
"continue," or the negative of these words. Actual outcomes and
results of operations and the timing of selected events may differ
materially from the results predicted, and any reported results
should not be considered as an indication of future performance. Such
statements are necessarily based on assumptions and estimates and are
subject to various risks and uncertainties, including those relating
to the possible invalidity of the underlying assumptions and
estimates and possible changes or developments in economic, business,
industry, market, legal and regulatory circumstances and conditions
and actions taken or omitted to be taken by third parties, including
customers, suppliers, business partners, potential licensees,
competitors and legislative, judicial and other governmental
authorities and officials. Factors that could cause or contribute to
such differences include, but are not limited to: unexpected outcomes
with respect to intellectual property enforcement actions, claims of
intellectual property infringement and general intellectual property
litigation; our ability to maintain, develop, monetize and protect
our patent portfolio for both the Company's health IT and
biotechnology intellectual property assets in the U.S. and
internationally; the timing of milestone payments in connection with
licensing our intellectual property; our ability to establish and
maintain strategic relationships; changes in our relationships with
our licensees; the risk the Company's products are not adopted or
viewed favorably by the healthcare community and consumer retail
market; business prospects, results of operations or financial
condition; risks related to the current uncertainty and instability
in financial and lending markets, including global economic
uncertainties; the timing and volume of sales and installations; the
length of sales cycles and the installation process; the market's
acceptance of new product and service introductions; competitive
product offerings and promotions; changes in government laws and
regulations including the 2009 HITECH Act and changes in Meaningful
Use and the 2010 Affordable Care Act; future changes in tax
legislation and initiatives in the healthcare industry; undetected
errors in our products; the possibility of interruption at our data
centers; risks related to third party vendors; risks related to
obtaining and integrating third-party licensed technology; risks
related to a security breach by third parties; risks associated with
recruitment and retention of key personnel; other litigation matters;
uncertainties associated with doing business internationally across
borders and territories; and additional risks discussed in the
Company's filings with the Securities and Exchange Commission,
including disclosures about the Company's relationship with the
Michael Bass Group since 2009. The Company is providing this
information as of the date of this release and, except as required by
applicable law, does not undertake any obligation to update any
forward-looking statements contained in this release as a result of
new information, future events or otherwise.   
CONTACT: 
Michael Selsman
Public Communications Co.
ms@publiccommunications.biz
(310) 922-7033 
 
 
Press spacebar to pause and continue. Press esc to stop.